Entrada Therapeutics (TRDA) News Today $17.93 +0.16 (+0.90%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Los Angeles Capital Management LLC Purchases Shares of 33,932 Entrada Therapeutics, Inc. (NASDAQ:TRDA)Los Angeles Capital Management LLC acquired a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 33,932 shares of the company's stock, vaNovember 17, 2024 | marketbeat.comNatarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockNovember 14, 2024 | insidertrades.comQ4 EPS Estimate for Entrada Therapeutics Lifted by AnalystEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company wiNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for TRDA FY2024 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now forecastNovember 7, 2024 | marketbeat.comFY2024 Earnings Forecast for TRDA Issued By William BlairEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at William Blair raised their FY2024 EPS estimates for Entrada Therapeutics in a report released on Tuesday, November 5th. William Blair analyst M. Minter now expects that the company will post earnings per share of $1.19November 7, 2024 | marketbeat.comEntrada Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 7, 2024 | finance.yahoo.comEntrada Therapeutics: Strong Buy Recommendation Backed by Promising Clinical Progress and Robust Financial HealthNovember 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)November 7, 2024 | markets.businessinsider.comOppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock PriceOppenheimer boosted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00HC Wainwright boosted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday.November 6, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month High - Here's What HappenedEntrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month High - What's Next?November 5, 2024 | marketbeat.comEntrada Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | markets.businessinsider.comShort Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1%Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,650,000 shares, a decline of 19.1% from the September 30th total of 2,040,000 shares. Currently, 7.6% of the shares of the company are short sold. Based on an average daily trading volume, of 139,800 shares, the short-interest ratio is currently 11.8 days.October 28, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 SharesOctober 19, 2024 | insidertrades.comNatarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 600 shares of the company's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $18.00, for a total value of $10,800.00. Following the completion of the sale, the insider now owns 183,216 shares of the company's stock, valued at $3,297,888. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.October 18, 2024 | marketbeat.comHere's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price StrengthOctober 15, 2024 | finance.yahoo.comRenaissance Technologies LLC Takes $636,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Renaissance Technologies LLC bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 44,600 shares of the company's stock, valued at approximateOctober 10, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEntrada Therapeutics Presents Data Supporting Advancement Of Duchenne FranchiseOctober 9, 2024 | markets.businessinsider.comEntrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyOctober 9, 2024 | globenewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) COO Sells $13,552.00 in StockOctober 1, 2024 | insidertrades.comEntrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentSeptember 24, 2024 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Trading Up 6.7%Entrada Therapeutics (NASDAQ:TRDA) Shares Up 6.7%September 19, 2024 | marketbeat.comāshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of DirectorsSeptember 17, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 SharesSeptember 11, 2024 | insidertrades.comNatarajan Sethuraman Sells 2,642 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockSeptember 11, 2024 | insidertrades.comEntrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramSeptember 6, 2024 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Stock Price Down 11.2%Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 11.2%September 3, 2024 | marketbeat.comEntrada Therapeutics Inc (TRDA) Gets a Buy from OppenheimerAugust 27, 2024 | markets.businessinsider.comEntrada Therapeutics' (TRDA) "Outperform" Rating Reaffirmed at OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $25.00 target price on shares of Entrada Therapeutics in a research report on Monday.August 26, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Stock Price Down 3%Entrada Therapeutics (NASDAQ:TRDA) Trading Down 3%August 21, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Sees Large Volume IncreaseEntrada Therapeutics (NASDAQ:TRDA) Sees Unusually-High Trading VolumeAugust 19, 2024 | marketbeat.comForecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved DrasticallyAugust 18, 2024 | finance.yahoo.comEntrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.90 EPSEntrada Therapeutics (NASDAQ:TRDA - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%.August 15, 2024 | marketbeat.comEntrada Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finance.yahoo.comTD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)August 14, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Entrada Therapeutics in a research report on Wednesday.August 14, 2024 | marketbeat.comEntrada Therapeutics (TRDA) Earnings Dates & ReportsAugust 9, 2024 | investing.comIs Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?August 7, 2024 | finance.yahoo.comEntrada Therapeutics Share Price (TRDA.US)August 6, 2024 | lse.co.ukEntrada Therapeutics (NASDAQ:TRDA) Sees Unusually-High Trading VolumeEntrada Therapeutics (NASDAQ:TRDA) Sees Strong Trading VolumeAugust 1, 2024 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Price T Rowe Associates Inc. MD decreased its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 8.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,753,August 1, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $28,496.00 in StockJuly 17, 2024 | insidertrades.comEntrada Therapeutics (NASDAQ:TRDA) Trading Down 3.6%Entrada Therapeutics (NASDAQ:TRDA) Trading Down 3.6%July 12, 2024 | marketbeat.comKory James Wentworth Sells 1,758 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockJuly 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $26,282.10 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 1,758 shares of the firm's stock in a transaction on Monday, July 8th. The shares were sold at an average price of $14.95, for a total value of $26,282.10. Following the sale, the chief financial officer now directly owns 81,412 shares of the company's stock, valued at $1,217,109.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.July 10, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Entrada Therapeutics, Inc. (NASDAQ:TRDA) Issued By HC WainwrightEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Entrada Therapeutics in a research report issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju now anticipates that the comJune 27, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Shares Up 4.1%Entrada Therapeutics (NASDAQ:TRDA) Shares Up 4.1%June 25, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Given New $18.00 Price Target at HC WainwrightHC Wainwright lowered their price objective on Entrada Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday.June 25, 2024 | marketbeat.comEntrada Therapeutics Announces $100 Million Registered Direct OfferingJune 24, 2024 | globenewswire.com Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW TRDA Media Mentions By Week TRDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼-0.300.46▲Average Medical News Sentiment TRDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼22▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amneal Pharmaceuticals News Scholar Rock News Zai Lab News Janux Therapeutics News Catalyst Pharmaceuticals News Iovance Biotherapeutics News Twist Bioscience News Longboard Pharmaceuticals News Arrowhead Pharmaceuticals News Protagonist Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
